Description
Kisspeptin-10 is a synthetic decapeptide derived from the KISS1 gene product and characterized in research literature as a central activator of hypothalamic GnRH secretion. The kisspeptin family was identified in the early 2000s as an upstream regulator of the reproductive axis, making the compound class one of the most important discoveries in modern reproductive endocrinology.
The research mechanism lies in the activation of the GPR54 receptor (also KISS1R) on hypothalamic GnRH neurons. In preclinical studies, kisspeptin-10 has been associated with potent stimulation of GnRH release, which downstream leads to LH and FSH increases from the anterior pituitary. This makes kisspeptin-10 a central research tool for studies on the HPG axis (hypothalamic-pituitary-gonadal).
A particularity of the kisspeptin axis: it is essential for the initiation of puberty. Mutations in the KISS1R gene lead to hypogonadotropic hypogonadism, documenting the central role in reproductive activation. In research setups, kisspeptin-10 is therefore frequently used in studies on reproductive axis regulation.
Kisspeptin-10 is the shortest biologically active form of the kisspeptin family (full kisspeptin-54 contains the kisspeptin-10 sequence at the C-terminus). The short form enables more efficient synthetic production and better characterization.
This variant is a ready-to-use nasal spray: 10mg of Kisspeptin-10 dissolved in 5 ml saline and 0.4 ml bacteriostatic water (5.4 ml in total), nothing to mix yourself. One spray (0.1 ml) delivers about 185 mcg. A bottle lasts for about 50 sprays. It is made fresh once you place your order and ships as an express item. As a powder for reconstitution, Kisspeptin-10 remains available in vials.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Kisspeptin-10 is described as well tolerated per study reports, but through its direct intervention in the reproductive axis it has its own profile of effects to consider.
Observed in research and user reports:
- Reproductive hormones: kisspeptin-10 is documented in studies as a potent activator of GnRH, LH and FSH secretion. Noticeable shifts in the reproductive hormone axis are the central expected effect.
- Nasal lining: the spray adds local effects: brief burning or tingling, an urge to sneeze, a runny nose and a bitter taste in the throat when solution runs down the back. With frequent use a dry lining or slight nosebleeds are possible.
- Circulation: isolated reports of brief warmth or mild dizziness shortly after application.
- Very short half-life: the short duration of action of kisspeptin-10 makes pharmacokinetics difficult to control in systemic setups.
- Limited long-term data: robust human studies exist primarily for short-term endocrine endpoints. Long-term data are largely lacking.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- The GPR54 gene as a regulator of puberty - New England Journal of Medicine 2003: Mutations in the receptor gene GPR54 cause hypogonadotropic hypogonadism in humans and mice, showing that the receptor is essential for normal GnRH physiology and puberty.
- Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men - Journal of Clinical Endocrinology & Metabolism 2011: In healthy men, an intravenous kisspeptin-10 bolus triggered a rapid, dose-dependent rise in LH. An infusion increased testosterone as well as LH pulse frequency and size.
- The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans - Journal of Clinical Endocrinology & Metabolism 2011: Kisspeptin-10 raised LH and FSH in men and in women during the preovulatory phase, but not in women during the follicular phase.
- Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans - EBioMedicine 2025: Randomized, placebo-controlled crossover study of nasal administration, though with kisspeptin-54 rather than kisspeptin-10: LH rose rapidly in healthy men and women and in women with hypothalamic amenorrhoea. No adverse events occurred.
